» Articles » PMID: 31787967

Liver-Mediated Adaptive Immune Tolerance

Overview
Journal Front Immunol
Date 2019 Dec 3
PMID 31787967
Citations 103
Authors
Affiliations
Soon will be listed here.
Abstract

The liver is an immunologically tolerant organ that is uniquely equipped to limit hypersensitivity to food-derived antigens and bacterial products through the portal vein and can feasibly accept liver allografts. The adaptive immune response is a major branch of the immune system that induces organ/tissue-localized and systematic responses against pathogens and tumors while promoting self-tolerance. Persistent infection of the liver with a virus or other pathogen typically results in tolerance, which is a key feature of the liver. The liver's immunosuppressive microenvironment means that hepatic adaptive immune cells become readily tolerogenic, promoting the death of effector cells and the "education" of regulatory cells. The above mechanisms may result in the clonal deletion, exhaustion, or inhibition of peripheral T cells, which are key players in the adaptive immune response. These tolerance mechanisms are believed to be responsible for almost all liver diseases. However, optimal protective adaptive immune responses may be achieved through checkpoint immunotherapy and the modulation of hepatic innate immune cells in the host. In this review, we focus on the mechanisms involved in hepatic adaptive immune tolerance, the liver diseases caused thereby, and the therapeutic strategies needed to overcome this tolerance.

Citing Articles

mRNA-LNP vaccine strategies: Effects of adjuvants on non-parenchymal liver cells and tolerance.

Svensson M, Limeres M, Zeyn Y, Gambaro R, Islan G, Berti I Mol Ther Methods Clin Dev. 2025; 33(1):101427.

PMID: 40027262 PMC: 11872076. DOI: 10.1016/j.omtm.2025.101427.


Pathogenetic development, diagnosis and clinical therapeutic approaches for liver metastasis from colorectal cancer (Review).

Jin Z, Li Y, Yi H, Wang M, Wang C, Du S Int J Oncol. 2025; 66(3).

PMID: 39950314 PMC: 11844340. DOI: 10.3892/ijo.2025.5728.


The liver's dilemma: sensing real danger in a sea of PAMPs: the (arterial) sinusoidal segment theory.

Henriques-Pons A, Vacani-Martins N, Dos Santos C, Meuser-Batista M Front Immunol. 2025; 15:1503063.

PMID: 39931578 PMC: 11808282. DOI: 10.3389/fimmu.2024.1503063.


Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances.

Kulbay M, Tuli N, Mazza M, Jaffer A, Juntipwong S, Marcotte E Biomedicines. 2025; 13(1).

PMID: 39857692 PMC: 11762644. DOI: 10.3390/biomedicines13010108.


Navigating liver cancer: Precision targeting for enhanced treatment outcomes.

Jain A, Mishra A, Hurkat P, Shilpi S, Mody N, Jain S Drug Deliv Transl Res. 2025; .

PMID: 39847205 DOI: 10.1007/s13346-024-01780-x.


References
1.
Peng H, Jiang X, Chen Y, Sojka D, Wei H, Gao X . Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J Clin Invest. 2013; 123(4):1444-56. PMC: 3613925. DOI: 10.1172/JCI66381. View

2.
Penaloza-MacMaster P, Kamphorst A, Wieland A, Araki K, Iyer S, West E . Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med. 2014; 211(9):1905-18. PMC: 4144726. DOI: 10.1084/jem.20132577. View

3.
Cuff A, Robertson F, Stegmann K, Pallett L, Maini M, Davidson B . Eomeshi NK Cells in Human Liver Are Long-Lived and Do Not Recirculate but Can Be Replenished from the Circulation. J Immunol. 2016; 197(11):4283-4291. PMC: 5114885. DOI: 10.4049/jimmunol.1601424. View

4.
Chyuan I, Hsu P . Tumor necrosis factor: The key to hepatitis B viral clearance. Cell Mol Immunol. 2018; 15(8):731-733. PMC: 6141607. DOI: 10.1038/cmi.2017.139. View

5.
Calne R, Sells R, Pena J, Davis D, Millard P, HERBERTSON B . Induction of immunological tolerance by porcine liver allografts. Nature. 1969; 223(5205):472-6. DOI: 10.1038/223472a0. View